...
首页> 外文期刊>Medicine. >Upregulation of microRNA-191 can serve as an independent prognostic marker for poor survival in prostate cancer
【24h】

Upregulation of microRNA-191 can serve as an independent prognostic marker for poor survival in prostate cancer

机译:microRNA-191的上调可作为前列腺癌生存不良的独立预后指标

获取原文
   

获取外文期刊封面封底 >>

       

摘要

MicroRNA-191 (miR-191) has been identified as being upregulated in several types of cancers, and plays the role of oncogene. The expression of miR-191 has been found to be upregulated in prostate cancer tissues as well as cell lines. In this study, we analyzed the correlation of miR-191 expression with clinicopathologic factors and prognosis in prostate cancer . Prostate cancer tissue samples and adjacent normal prostate tissue samples were collected from 146 patients who underwent laparoscopic radical prostatectomy between April 2013 and March 2018. Student two-tailed t -test was used for comparisons of 2 independent groups. The relationships between miR-191 expression and different clinicopathological characteristics were evaluated using the Chi-squared test. Kaplan–Meier survival plots and log-rank tests were used to assess the differences in overall survival of the different subgroups of prostate cancer patients. miR-191 expression was significantly higher in prostate cancer tissues compared with normal adjacent prostate tissues ( P .001). miR-191 expression was observed to be significantly correlated with Gleason score ( P .001), pelvic lymph node metastasis ( P = .006), bone metastases ( P .001), and T stage ( P = .005). Kaplan–Meier analysis showed that patients with higher levels of miR-191 had significantly poorer survival than those with lower expression of this miRNA in prostate cancer patients (log rank test, P = .011). Multivariate analysis revealed that miR-191 expression (hazard ratio [HR] = 2.311, 95% confidence interval, [CI]: 1.666–9.006; P = .027) was independently associated with the overall survival of prostate cancer patients. Our results demonstrated that miR-191 might serve as an independent prognostic indicator for prostate cancer patients.
机译:MicroRNA-191(miR-191)已在多种类型的癌症中被上调,并起着癌基因的作用。已经发现miR-191的表达在前列腺癌组织以及细胞系中被上调。在这项研究中,我们分析了miR-191表达与前列腺癌的临床病理因素和预后的相关性。从2013年4月至2018年3月之间接受腹腔镜根治性前列腺切除术的146例患者中收集前列腺癌组织样本和邻近的正常前列腺组织样本。使用学生两尾t检验对两组进行比较。使用卡方检验评估了miR-191表达与不同临床病理特征之间的关系。 Kaplan–Meier生存图和对数秩检验用于评估前列腺癌患者不同亚组的总体生存差异。与正常的邻近前列腺组织相比,miR-191在前列腺癌组织中的表达明显更高(P <.001)。观察到miR-191表达与格里森评分(P <.001),骨盆淋巴结转移(P = .006),骨转移(P <.001)和T期(P = .005)显着相关。 Kaplan–Meier分析表明,在前列腺癌患者中,miR-191水平较高的患者比该miRNA表达水平较低的患者生存率显着降低(对数秩检验,P = 0.011)。多变量分析显示,miR-191表达(危险比[HR] = 2.311,95%置信区间,[CI]:1.666–9.006; P = .027)与前列腺癌患者的整体生存率独立相关。我们的结果表明,miR-191可以作为前列腺癌患者的独立预后指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号